BioCentury | Nov 4, 2020
Deals

Novartis vets Jimenez, Fishman thread digital into fabric of new VC firm Aditum, launch Tempero

...as HTL0014242, was designed by Sosei Heptares’ GPCR...
...develop OX1 and OX2 positive modulators of GPCR.TARGETSmGluR5...
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...Modality-agnostic newco gives cytokines the GPCR treatment for cancer and autoimmunity By  Karen Tkach Tuzman, Associate...
...these cytokines to endow them with drug-like properties,” similar to what has been done for GPCR-targeting...
BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

Escient raises $77.5M B roundEscient Pharmaceuticals Inc. announced Monday the start of a Phase I/Ib trial of lead program EP547 for cholestatic and uremic pruritis alongside a $77.5 million series B round led by Sanofi...
BioCentury | Jun 26, 2020
Deals

Sosei Heptares gains new GPCR discovery partner in AbbVie

...Sosei Heptares’ GPCR-targeting platform is continuing to draw attention from pharma with a deal with AbbVie...
...Sosei Group Corp. (Tokyo:4565) unit will use its StaR platform to discover small molecules against GPCR...
...Takeda deal is gastrointestinal diseases including gut inflammation and motility disorders. Sandi Wong, Assistant Editor AbbVie Inc. Sosei Co. GPCR Sosei...
BioCentury | Jun 24, 2020
Finance

Expect more company creation by BGV with its €105M fourth fund

...new fund. Notable investments from its third fund include metabolic orphan drug company Azafaros B.V., GPCR...
...has more than €220 million in assets under management. Targets BTK - Bruton’s tyrosine kinase GPCR...
BioCentury | Jun 13, 2020
Management Tracks

Sawyers to head AACR next year; plus Quell, CalciMedica, Bigfoot, Celyad, Praxis, Affimed and more

...succeeds Florian Smith, who passed away in February. Confo Therapeutics N.V. , which is developing GPCR-modulating...
BioCentury | Jun 11, 2020
Deals

June 10 Quick Takes: Lilly enters deal with Evox on exosome therapies; plus Sanofi-Alphamab, CSL-Vitaeris, Canbridge-UMass and Find’s debut

...research on gene therapies for rare genetic diseases, with a focus on neuromuscular conditions. Canadian GPCR...
BioCentury | Jun 10, 2020
Emerging Company Profile

With $50M from Versant, Lycia takes targeted degradation outside the cell

...induced endolysosomal degradation of extracellular proteins by linking one ligand that binds the cell surface GPCR...
BioCentury | May 20, 2020
Tools & Techniques

Octant emerges with $30M to untangle, exploit pathways hit by dirty drugs

...using genetic bar codes to sort out the pathways behind the therapeutic effects of dirty GPCR...
BioCentury | Apr 15, 2020
Emerging Company Profile

Backed by Third Rock-led syndicate, MOMA seeks new ATP-powered targets by interrogating 'molecular machines'

...and attack it like you would a kinase, or a nuclear hormone receptor or a GPCR."...
Items per page:
1 - 10 of 502